Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Non-Current Assets (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Non-Current Assets data on record, last reported at $25.9 million in Q4 2025.

  • For Q4 2025, Non-Current Assets rose 52.99% year-over-year to $25.9 million; the TTM value through Dec 2025 reached $86.0 million, up 19.57%, while the annual FY2025 figure was $25.9 million, 52.99% up from the prior year.
  • Non-Current Assets reached $25.9 million in Q4 2025 per OCUL's latest filing, up from $23.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $25.9 million in Q4 2025 and bottomed at $12.7 million in Q2 2022.
  • Average Non-Current Assets over 5 years is $17.8 million, with a median of $18.1 million recorded in 2025.
  • Peak YoY movement for Non-Current Assets: skyrocketed 71.35% in 2023, then decreased 17.84% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $13.6 million in 2021, then soared by 44.71% to $19.7 million in 2022, then grew by 0.83% to $19.8 million in 2023, then fell by 14.51% to $16.9 million in 2024, then surged by 52.99% to $25.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $25.9 million in Q4 2025, $23.9 million in Q3 2025, and $18.0 million in Q2 2025.